PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
This observational cohort study enrolled 922 Portuguese individuals from the PREVADIAB2 cohort to investigate the role of PON1 genetic variants in metabolic liver disease. The primary exposure was PON1 genetic variants rs2057681 and rs854572, along with their haplotypes, while the primary outcome was PONase activity. Secondary outcomes included dysglycemia and liver fibrosis risk within the context of metabolic dysfunction-associated steatotic liver disease (MASLD).
Main results indicated that specific combinations of rs854572-rs2057681 haplotypes differentially modulated PONase activity. These genetic configurations conferred either risk or protection against dysglycemia and liver fibrosis, with the direction of effect dependent on the rs2057681 genotype context. Conversely, dysmetabolic phenotypes did not directly correlate with measured PONase activity levels.
Safety and tolerability data were not reported in this genetic association study. Key limitations include the finding that PONase activity alone does not shape disease susceptibility, as associations are described as dependent on genetic configuration rather than enzyme activity. The study setting was Portugal, and no specific follow-up duration was reported. Practice relevance supports using PON1 genetic information to uncover predisposition to dysmetabolic conditions and for risk stratification in metabolic liver disease, noting that causality cannot be inferred from this observational design.